Anti-DPD antibody [7D4] (ab54797)
Key features and details
- Mouse monoclonal [7D4] to DPD
- Suitable for: WB, ICC/IF, Flow Cyt
- Reacts with: Human
- Isotype: IgG1
Get better batch-to-batch reproducibility with a recombinant antibody
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Overview
-
Product name
Anti-DPD antibody [7D4]
See all DPD primary antibodies -
Description
Mouse monoclonal [7D4] to DPD -
Host species
Mouse -
Tested applications
Suitable for: WB, ICC/IF, Flow Cytmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment corresponding to Human DPD aa 1-111.
-
General notes
This product was changed from ascites to tissue culture supernatant on 12/3/19. Please note that the dilutions may need to be adjusted accordingly. If you have any questions, please do not hesitate to contact our scientific support team.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
pH: 7.4 -
Concentration information loading...
-
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
7D4 -
Isotype
IgG1 -
Light chain type
kappa -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab54797 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use at an assay dependent concentration. Predicted molecular weight: 111 kDa.
|
|
ICC/IF |
Use at an assay dependent concentration.
|
|
Flow Cyt |
Use at an assay dependent concentration.
ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody. |
Notes |
---|
WB
Use at an assay dependent concentration. Predicted molecular weight: 111 kDa. |
ICC/IF
Use at an assay dependent concentration. |
Flow Cyt
Use at an assay dependent concentration. ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody. |
Target
-
Function
Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil. -
Tissue specificity
Found in most tissues with greatest activity found in liver and peripheral blood mononuclear cells. -
Pathway
Amino-acid biosynthesis; beta-alanine biosynthesis. -
Involvement in disease
Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) [MIM:274270]; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma. -
Sequence similarities
Belongs to the dihydropyrimidine dehydrogenase family.
Contains 3 4Fe-4S ferredoxin-type domains. -
Cellular localization
Cytoplasm. - Information by UniProt
-
Database links
- Entrez Gene: 1806 Human
- GenBank: AAH08379 Human
- Omim: 274270 Human
- Omim: 612779 Human
- SwissProt: Q12882 Human
- Unigene: 335034 Human
-
Alternative names
- DHP antibody
- DHPDHase antibody
- Dihydropyrimidine dehydrogenase [NADP(+)] antibody
see all
Images
-
DPD antibody (ab54797) at 1ug/lane + HeLa cell lysate at 25ug/lane.
This image was generated using the ascites version of the product.
-
ab54797 at 10 ug/ml staining DPD in human Hela cells by Immunocytochemistry / Immunofluorescence.
This image was generated using the ascites version of the product.
-
Overlay histogram showing HepG2 cells stained with ab54797 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab54797, 1µg/1x106 cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HepG2 cells fixed with 100% methanol (5 min)/permeabilized in 0.1% PBS-Tween used under the same conditions.
This image was generated using the ascites version of the product.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (10)
ab54797 has been referenced in 10 publications.
- Tsukahara S et al. Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine. Sci Rep 12:8535 (2022). PubMed: 35595780
- Zhao H et al. Single-Cell Transcriptomics of Human Oocytes: Environment-Driven Metabolic Competition and Compensatory Mechanisms During Oocyte Maturation. Antioxid Redox Signal 30:542-559 (2019). PubMed: 29486586
- Qin F et al. Effect of dihydropyrimidine dehydrogenase single nucleotide polymorphisms on prognosis of breast cancer patients with chemotherapy. Oncotarget 8:112060-112075 (2017). PubMed: 29340111
- Oba A et al. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci 23:480-8 (2016). PubMed: 27247050
- Wu R et al. Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter. Cancer Res 76:6362-6373 (2016). WB . PubMed: 27578004
- Offer SM et al. microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol Cancer Ther 13:742-51 (2014). WB . PubMed: 24401318
- Offer SM et al. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res 74:2545-54 (2014). WB . PubMed: 24648345
- Offer SM et al. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res 73:1958-68 (2013). WB ; Human . PubMed: 23328581
- Yoo BK et al. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest 119:465-77 (2009). IHC-P ; Human . PubMed: 19221438
- Yoo BK et al. Identification of genes conferring resistance to 5-fluorouracil. Proc Natl Acad Sci U S A 106:12938-43 (2009). WB ; Human . PubMed: 19622726